Terms: = Kidney tumors AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Treatment
135 results:
1. Humoral complementomics - exploration of noninvasive complement biomarkers as predictors of renal cancer progression.
Revel M; Rezola Artero M; Hamidi H; Grunenwald A; Blasco L; Vano YA; Marie Oudard S; Sanchez-Salas R; Macek P; Rodriguez Sanchez L; Cathelineau X; Vedié B; Sautes-Fridman C; Herman Fridman W; Roumenina LT; Dragon-Durey MA
Oncoimmunology; 2024; 13(1):2328433. PubMed ID: 38487624
[TBL] [Abstract] [Full Text] [Related]
2. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
3. The Effect of treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma].
Chen S; Ban CR; Zhang XT; Chen YP; Ren CH; Chen H
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):155-161. PubMed ID: 38281783
[No Abstract] [Full Text] [Related]
5. Genomic alterations and diagnosis of renal cancer.
Zhang X; Bolck HA; Rupp NJ; Moch H
Virchows Arch; 2024 Feb; 484(2):323-337. PubMed ID: 37999735
[TBL] [Abstract] [Full Text] [Related]
6. Factors influencing the detection rate of fumarate peak in
Pan S; Wang J; Liu G; Zhang J; Song Y; Kong W; Zhou Y; Wu G
Clin Radiol; 2024 Jan; 79(1):e80-e88. PubMed ID: 37923625
[TBL] [Abstract] [Full Text] [Related]
7. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract] [Full Text] [Related]
8. FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in kidney Cancer.
Wilde BR; Chakraborty N; Matulionis N; Hernandez S; Ueno D; Gee ME; Esplin ED; Ouyang K; Nykamp K; Shuch B; Christofk HR
Cancer Discov; 2023 Sep; 13(9):2072-2089. PubMed ID: 37255402
[TBL] [Abstract] [Full Text] [Related]
9. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.
Zheng L; Zhu ZR; Sneh T; Zhang WT; Wang ZY; Wu GY; He W; Qi HG; Wang H; Wu XY; Fernández-García J; Abramovich I; Xu YZ; Zhang J; Gottlieb E
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37053010
[TBL] [Abstract] [Full Text] [Related]
10. treatment Strategies for Hereditary kidney Cancer: Current Recommendations and Updates.
Singh S; Chaurasia A; Gopal N; Malayeri A; Ball MW
Discov Med; 2022; 34(173):205-220. PubMed ID: 36602871
[TBL] [Abstract] [Full Text] [Related]
11. Comparative analyses of tumour immune microenvironment between collecting duct carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Umekita S; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Oda Y
J Clin Pathol; 2024 Jan; 77(2):105-110. PubMed ID: 36347592
[TBL] [Abstract] [Full Text] [Related]
12. [Consensus on clinical diagnosis and treatment of fumarate hydratase-deficient renal cell carcinoma].
Rare Kidney Cancer Collaborative Group, Genitourinary Cancer Committee, China Anti-Cancer Association
Zhonghua Wai Ke Za Zhi; 2022 Nov; 60(11):961-968. PubMed ID: 36323576
[TBL] [Abstract] [Full Text] [Related]
13. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and hlrcc-Associated Renal Cell Carcinoma.
Ligon JA; Sundby RT; Wedekind MF; Arnaldez FI; Del Rivero J; Wiener L; Srinivasan R; Spencer M; Carbonell A; Lei H; Shern J; Steinberg SM; Figg WD; Peer CJ; Zimmerman S; Moraly J; Xu X; Fox S; Chan K; Barbato MI; Andresson T; Taylor N; Pacak K; Killian JK; Dombi E; Linehan WM; Miettinen M; Piekarz R; Helman LJ; Meltzer P; Widemann B; Glod J
Clin Cancer Res; 2023 Jan; 29(2):341-348. PubMed ID: 36302175
[TBL] [Abstract] [Full Text] [Related]
14. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
15. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy.
Ueno D; Vasquez JC; Sule A; Liang J; van Doorn J; Sundaram R; Friedman S; Caliliw R; Ohtake S; Bao X; Li J; Ye H; Boyd K; Huang RR; Dodson J; Boutros P; Bindra RS; Shuch B
Oncotarget; 2022; 13():1054-1067. PubMed ID: 36128328
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract] [Full Text] [Related]
17. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates.
Lee CH; Voss MH; Carlo MI; Chen YB; Zucker M; Knezevic A; Lefkowitz RA; Shapnik N; Dadoun C; Reznik E; Shah NJ; Owens CN; McHugh DJ; Aggen DH; Laccetti AL; Kotecha R; Feldman DR; Motzer RJ
J Clin Oncol; 2022 Jul; 40(21):2333-2341. PubMed ID: 35298296
[TBL] [Abstract] [Full Text] [Related]
18. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
[TBL] [Abstract] [Full Text] [Related]
19. Cyst(e)inase-Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer.
Kerimoglu B; Lamb C; McPherson RD; Ergen E; Stone EM; Ooi A
Mol Cancer Ther; 2022 Mar; 21(3):419-426. PubMed ID: 35086957
[TBL] [Abstract] [Full Text] [Related]
20. Lucanthone, Autophagy Inhibitor, Enhances the Apoptotic Effects of TRAIL through miR-216a-5p-Mediated DR5 Upregulation and DUB3-Mediated mcl-1 Downregulation.
Yoon JY; Woo SM; Seo SU; Song SR; Lee SG; Kwon TK
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008442
[TBL] [Abstract] [Full Text] [Related]
[Next]
